Reducing lipids for CV protection in CKD patients—current evidence

Slides:

Advertisements

Similar presentations

Volume 80, Issue 6, Pages (September 2011)

Advertisements

Copyright © 2003 American Medical Association. All rights reserved.

Volume 62, Issue 6, Pages (December 2002)

Uremic lung: new insights into a forgotten condition

Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward Adeera Levin, Paul E. Stevens Kidney International

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient Christoph Wanner,

Renal manifestations in Fabry disease and therapeutic options

Volume 80, Issue 6, Pages (September 2011)

Anemia management in chronic kidney disease

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Volume 79, Issue 9, Pages (May 2011)

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig

Volume 80, Issue 11, Pages (December 2011)

Microvascular responses to sepsis: clinical significance

Obesity, inflammation, and kidney disease

Innate immunity as a driving force in renal disease

Xenobiotic receptor meets NF-κB, a collision in the small bowel

Reassessment of the care of the patient with chronic kidney disease

Progression of renal failure and hypertensive nephrosclerosis

Verotoxin biology: molecular events in vascular endothelial injury

Volume 85, Issue 3, Pages (March 2014)

Volume 85, Issue 3, Pages (March 2014)

Volume 150, Issue 2, Pages (August 2016)

Volume 70, Pages S21-S25 (December 2006)

Abnormalities in lipoprotein metabolism in hemodialysis patients

Infection and chronic allograft dysfunction

Volume 74, Issue 3, Pages (August 2008)

Lipid redistribution in renal dysfunction

Volume 82, Issue 4, Pages (August 2012)

Volume 71, Issue 11, Pages (June 2007)

Nephrology Crosswords: Hemodialysis

Endothelial Cell Injury in Cardiovascular Surgery: The Systemic Inflammatory Response1 Edward M Boyle, MD, Timothy H Pohlman, MD, Marion C Johnson, MD,

Thomas Quaschning, Jan Galle, Christoph Wanner

Dyslipidemia in children with chronic kidney disease

Margus Annuk, Mihkel Zilmer, Bengt Fellström

Volume 85, Issue 2, Pages (January 2014)

Claudine S. Bonder, Lisa M. Ebert Kidney International

Correction Journal of Vascular Surgery

Volume 88, Issue 4, Pages (October 2015)

Volume 73, Issue 12, Pages (June 2008)

Endothelial dysfunction and inflammation: What is the link?

A physician's perseverance uncovers problems in a key nephrology study

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 79, Issue 9, Pages (May 2011)

AGEs in foods: Do they play a role in uremia?

Volume 87, Issue 1, Pages (January 2015)

Volume 67, Issue 4, Pages (April 2005)

Anti-Cytokine Therapies in Response to Systemic Infection

Simvastatin in nephrotic syndrome

Nephrology Crossword: Glomerulonephritis

Volume 56, Pages S235-S237 (July 1999)

Volume 87, Issue 5, Pages (May 2015)

Volume 78, Issue 8, Pages (October 2010)

Mediterranean diets: are they practical in the Western world?

Volume 82, Issue 9, Pages (November 2012)

Volume 80, Issue 11, Pages (December 2011)

Cardio-Kidney-Damage: a unifying concept

Volume 81, Issue 1, Pages 7-9 (January 2012)

The valuable contribution of observational studies to nephrology

Phosphate binders on iron basis: A new perspective?

Volume 55, Pages S3-S16 (June 1999)

Volume 83, Issue 4, Pages (April 2013)

Volume 80, Issue 10, Pages (November 2011)

David A. Ferenbach, David C. Kluth, Jeremy Hughes Kidney International

Sundararaman Swaminathan, Matthew D. Griffin Kidney International

Adiponectin: good, bad, or just plain ugly?

Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor Senthilkumar Alagesan, Matthew D. Griffin

Deborah J. Kozik, DO, James S. Tweddell, MD

Volume 74, Pages S4-S9 (December 2008)

Presentation transcript:

Reducing lipids for CV protection in CKD patients—current evidence Christoph Wanner, Eberhard Ritz Kidney International Volume 74, Pages S24-S28 (December 2008) DOI: 10.1038/ki.2008.520 Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 1 Triglyceride-enriched very low-density lipoprotein (VLDL) activates nuclear factor-kappa B (NF-κB), which plays a key role in activating a spectrum of pro-inflammatory genes, leading to endothelial dysfunction and oxidative stress. NFκB, nuclear factor κB; IL-6, interleukin 6; COX-2, cyclooxygenase-2; TNF-α, tumor necrosis factor-α; ICAM, intracellular adhesion molecule; VCAM, vascular cell adhesion molecule; ApoCIII, apolipoprotein CIII. Kidney International 2008 74, S24-S28DOI: (10.1038/ki.2008.520) Copyright © 2008 International Society of Nephrology Terms and Conditions